KRAS and acute lymphoblastic leukemia: T cell responses to the pooled DENV peptides (DENV-ALL) (p = 0.02) were higher in PBMCs derived from patients with DF than DHF patients and the NS3-specific responses showed a trend to be higher in those with DF than DHF (Fig 1A).